Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Brinzolamide + Brimonidine, Atc S01ec24 for the Period September 1St, 2024 - August 31St, 2026

Renewal Transformer

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Dapagliflozin (A10bk01) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Evolocumab (C10ax13) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Midazolam (N05cd08) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Contracts in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Interferon Beta-1A, Intramuscular Injection (L03ab07) as Part of a So-Called O...

Implementation of the Rescue Service in the Rescue Service Area of ​​The Central Saxony District

Open House Drug Discount Agreements Emtricitabine, Tenofovir Disoproxil and Rilpivirine, Atc J05ar08

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Sodium Oxybate (N07xx04) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Botulinum Toxin Type A, Finished Drug Name Botox(R), Atc M03ax21